Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSK46256
- Development stage
- Phase 1
- Lead developer
- Haisco Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HSK46256 is an orally bioavailable, highly selective small molecule inhibitor of Poly (ADP-ribose) polymerase 1 (PARP1), developed by Shenyang Haisco Pharmaceutical. Unlike first-generation PARP inhibitors that inhibit both PARP1 and PARP2, HSK46256 is designed to selectively target PARP1 to potentially reduce hematological toxicities associated with PARP2 inhibition, such as anemia and thrombocytopenia. It is currently being evaluated in Phase I clinical trials in China for the treatment of advanced or metastatic solid tumors harboring specific DNA damage repair (DDR) gene mutations, such as BRCA1/2 mutations.
02
Targets
PARP2 (Poly (adp-ribose) polymerase 2)PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on HSK46256.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSK46256.